Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose REGN1908-1909 study in cat-allergic allergic rhinitis with nasal allergen challenge
NL-OMON40738Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in allergic rhinitis (AR) and cat allergy comparing REGN1908-1909 with Placebo (2 arms). Primary endpoints: Change in TNSS AUC on day 8 versus pretreatment challenge, VAS nasal symptoms score and 1 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
REGN1908-1909
03
Conditions
allergic rhinitis (AR)cat allergy
Beyond the preview
Go deeper on NL-OMON40738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40738.